Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • Health Equity through Her Lens
    • The Health Equity podcast
    • Access insights
    • Health Equity through Her Lens
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Date

29 September 2023

When the drugs don’t work: can we do anything about antimicrobial resistance?

Sarah Johnson, writing for the Guardian, looks at the global threat of antimicrobial resistance (AMR). Using the tragic case study of a child in Nigeria to illustrate the issue, the article quotes forecasts that AMR could kill 4.1 million people in Africa by 2050.

Direct links

Read the article

Sarah spoke to Marijn Verhoef, the Foundation's Director of Operations and Research, about lack of access to the right medicine as a major driver of AMR, particularly in sub-Saharan Africa.

"In sub-Saharan Africa, in most regions, either patients have no access to medicine at all or access to suboptimal treatments - either antibiotics for a different type of infection, falsified medicines or antibiotics reserved for treating the most difficult infections.''

Read the Foundation's report on lack of access as a driver of AMR.

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved